The weight management industry is moving through a major shift as pharmaceutical treatments become an increasingly visible part of obesity care. GLP-1-based medicines have moved from being primarily associated with metabolic disease management to becoming a major category within weight loss treatment, supported by rising obesity prevalence, clinical efficacy, greater awareness, and expanding access through healthcare and pharmacy channels.

The global GLP-1 Agonists Weight Loss Drugs Market was valued at USD 13.8 billion in 2024 and is projected to reach USD 48.8 billion by 2030, growing at a CAGR of 18.5% from 2025 to 2030. North America represented the largest regional market, accounting for 75.5% of global revenue in 2024.

Why GLP-1 Therapies Are Gaining So Much Attention

The expansion of this market is closely connected with the growing global burden of overweight and obesity. According to the information provided in the market source, 2.5 billion adults were overweight in 2022, including 890 million people with obesity. Increasing awareness of obesity as a long-term health issue is encouraging greater attention toward both lifestyle-based and pharmacological interventions.

GLP-1 therapies have gained visibility because of their demonstrated weight-reduction effects and their growing use in structured weight-management programs. Semaglutide and tirzepatide have become particularly prominent, while continued pharmaceutical research is widening the potential treatment landscape. Consumer awareness has also become an important part of the market story. Social media discussions, celebrity endorsements, and patient experiences have contributed to broader public interest in GLP-1-based weight loss treatments.

Download a free sample report or claim your copy of this full market intelligence report

Semaglutide Leads, While Tirzepatide Changes the Competitive Picture

Drug-level competition is one of the defining features of the market.

Semaglutide (Wegovy) held the largest revenue share, accounting for 60.70% in 2024. Its market position has been supported by clinical evidence, regulatory approvals, physician adoption, and increasing awareness of weight-management applications.

At the same time, tirzepatide (Zepbound) is expected to record the fastest growth during the forecast period. Unlike a conventional GLP-1-only approach, tirzepatide acts on both GIP and GLP-1 receptors, creating a distinct mechanism within the weight-loss drug landscape. The FDA approved Zepbound in November 2023 for chronic weight management in adults with obesity or overweight, alongside diet and exercise. This competition is encouraging pharmaceutical companies to focus increasingly on efficacy, convenience, treatment adherence, and new mechanisms of action.

The Market Is Moving Beyond Injectable Therapies

Injectable treatments currently dominate the market. The parenteral segment accounted for 92.7% of revenue in 2024, reflecting the established position of injectable GLP-1 therapies and the convenience of dosing schedules associated with leading products.

However, the next stage of market development could look considerably different.

Oral formulations are receiving increasing attention because they can provide a non-injectable option for long-term weight management. Advances in controlled-release technologies and drug delivery are supporting research into formulations designed to improve convenience and treatment adherence.

The evolution of the market is therefore not simply about introducing more drugs. It is also about creating different ways for patients to receive those therapies.

Pharmacies Are Becoming an Important Access Point

Distribution is another area undergoing significant change.

Retail pharmacies represented 55.46% of market revenue in 2024, making them the leading distribution channel. Their importance reflects the growing demand for accessible weight-management treatments and the ability of pharmacies to provide medication-related services alongside product distribution.

Hospital pharmacies continue to play an important role, particularly within healthcare settings where treatment is integrated with professional supervision.

Meanwhile, the broader pharmacy segment is gaining attention through mail-order services, online pharmacies, compounding pharmacies, and other specialized channels. The expansion of telemedicine and digital healthcare platforms is further changing how patients can connect with healthcare professionals and access treatment.

Regional Markets Are Developing at Different Speeds

North America remains the center of the global market, with the U.S. accounting for 95.23% of the North American market in 2024. Strong demand for semaglutide and tirzepatide, established healthcare infrastructure, and broad pharmacy distribution have contributed to the region's position.

Europe is also experiencing increasing adoption of GLP-1 therapies. The UK, Germany, and France represent important markets as awareness of obesity management and pharmaceutical treatment options increases.

Asia Pacific presents another important growth environment. China, India, Japan, and Australia are seeing greater attention toward weight-management therapies as healthcare access and obesity awareness develop. Japan is seeing demand for semaglutide and tirzepatide, while China's expanding healthcare ecosystem is supporting wider availability.

In Latin America, Brazil is a significant market, while Saudi Arabia and South Africa are among the notable markets within MEA.

Access and Affordability Remain Critical

Rapid market growth does not mean that adoption is without challenges.

The cost of GLP-1 therapies can affect accessibility, particularly in markets where insurance reimbursement is limited. Supply-chain pressures can also influence availability when demand rises rapidly. Regulation represents another important consideration. Agencies such as the FDA and EMA apply stringent requirements around clinical development, efficacy, and safety. These requirements support patient safety but can also increase development timelines and barriers to market entry.

The market also operates alongside other approaches to weight management, including lifestyle interventions, bariatric surgery, and alternative pharmacological treatments. Consequently, long-term adoption will depend on how GLP-1 therapies fit within broader obesity-management strategies.

Looking for more in-depth data focusing on specific segments or regions? Get this report customized with inclusion of custom data sets to suit your exact business needs.

Innovation Is Expanding the Opportunity

Pharmaceutical development is increasingly focused on improving the overall treatment experience rather than relying solely on established injectable formulations.

Areas attracting attention include:

• Oral GLP-1 therapies
• Dual and triple agonists
• Combination treatments
• Longer-acting formulations
• Alternative delivery technologies
• Personalized weight-management approaches
• Therapies designed to improve adherence and tolerability

Mergers, acquisitions, and strategic expansion are also shaping the competitive environment as pharmaceutical companies seek access to new formulations, technologies, and obesity-treatment portfolios.

Key Companies

The competitive landscape includes major pharmaceutical companies developing and commercializing therapies across the GLP-1 and broader metabolic-treatment space.

• Eli Lilly and Company
• Pfizer Inc.
• Novo Nordisk A/S

Explore the full list of profiled companies operating in this market with recent strategic initiatives

These companies are competing through drug development, clinical research, manufacturing expansion, regulatory approvals, formulation innovation, and broader distribution strategies.

What the Market Could Look Like by 2030

The GLP-1 Agonists Weight Loss Drugs Market is developing into a much broader pharmaceutical ecosystem. The opportunity is no longer limited to a small number of injectable therapies. Drug innovation, oral formulations, new mechanisms, digital healthcare, pharmacy access, and changing approaches to obesity management are all influencing the market's direction.

With the market projected to expand from USD 13.8 billion in 2024 to USD 48.8 billion by 2030, the coming years will be shaped by how pharmaceutical companies balance treatment efficacy with accessibility, supply, regulatory requirements, convenience, and continued innovation.

About us:

Grand View Research, a market research and consulting company, provides syndicated research reports, customized research reports, and consulting services. Grand View Research database is used by the world's renowned academic institutions and Fortune 500 companies to understand the global and regional business environment. Our database features thousands of statistics and in-depth analysis on 46 industries in 25 major countries worldwide.